The Drugs Controller General of India (DCGI) has given approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India.
This will hasten the development of the COVID-19 vaccine.
Basic Facts
On July 20, the initial trial results for the vaccine candidate, Covishield, which were made public by Oxford University had shown promising results.
Serum Institute of India, the world’s largest vaccine manufacturer by the number of doses produced and sold globally, has entered a manufacturing partnership with biopharma major AstraZeneca to produce the Oxford vaccine.
